Methimazole (Tapazole) Cost in New York 2026

What Does Methimazole Actually Cost in New York Right Now?

Generic methimazole costs approximately $15 per month at New York retail pharmacies on a cash-pay basis in 2026. Brand-name Tapazole (Pfizer) carries a manufacturer list price near $80 per month, though almost no patient pays that figure once insurance or discount programs are applied. GoodRx coupons at CVS, Walgreens, Rite Aid, and Walmart locations across New York City, Buffalo, and Albany frequently bring the price to $9, $12 for a 30-day supply of 5 mg or 10 mg tablets.

Methimazole is classified as a thyroid synthesis inhibitor. It blocks thyroid peroxidase, the enzyme that oxidizes iodide and couples iodotyrosines to produce triiodothyronine (T3) and thyroxine (T4). The FDA first approved it under NDA 008492, and the current prescribing information is available through the FDA's accessdata portal [1]. Because the molecule is off-patent and manufactured by multiple generic firms, pharmacy acquisition cost is low, which is why cash prices are well below the brand list price.

A 2022 analysis in JAMA Internal Medicine found that generic drug list prices at independent versus chain pharmacies varied by as much as 447% for the same molecule within a single metro area [2]. New York City pharmacies show similar dispersion for methimazole. Calling three to five pharmacies or running a GoodRx search before filling the prescription can save $20, $40 per fill.

Thyroid disease affects roughly 20 million Americans, with Graves disease accounting for 60 to 80% of hyperthyroidism cases [3]. Methimazole is the preferred antithyroid drug in the United States, a recommendation formalized in the 2016 American Thyroid Association (ATA) guidelines: "We recommend methimazole be used in virtually every patient who chooses antithyroid drug therapy" [4].

How New York Medicaid Covers Methimazole

New York Medicaid covers methimazole, but requires prior authorization (PA) before the claim processes. The PA requirement is standard for antithyroid agents in most Medicaid preferred drug lists (PDLs). Prescribers typically submit documentation confirming a diagnosis of hyperthyroidism or Graves disease, a recent thyroid-stimulating hormone (TSH) level below the normal reference range, and clinical rationale for antithyroid drug therapy rather than radioactive iodine or surgery.

New York's Medicaid pharmacy benefit is administered through the Fee-for-Service (FFS) program and multiple managed care organizations (MCOs) including Healthfirst, MetroPlus, and Fidelis Care. Each MCO maintains its own formulary, so PA criteria may differ slightly between plans. The New York State Department of Health publishes the FFS PDL on its Medicaid website, and methimazole appears on the preferred tier [5].

Patients enrolled in the Medicaid Managed Care program who are denied coverage can request a formulary exception or file an internal appeal within 30 days of the denial. Under New York State Insurance Law Section 4802, managed care plans must provide an expedited appeal decision within 72 hours if the prescriber certifies that delay would seriously jeopardize health [6]. For a patient in thyroid storm or severely symptomatic hyperthyroidism, that expedited pathway is available.

Low-income New Yorkers who do not yet have Medicaid may qualify through NY State of Health, the state's official health plan marketplace. Open enrollment and special enrollment periods allow income-based subsidies that can reduce monthly premiums to $0 for households below 150% of the federal poverty level [7].

Is Compounded Methimazole Legal in New York?

Compounded methimazole is legal in New York when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. The Drug Quality and Security Act of 2013 established the federal framework distinguishing 503A (patient-specific, traditional compounding) from 503B (outsourcing facilities for office stock) [8]. New York compounds this federal oversight with its own Board of Pharmacy regulations under Title 8 NYCRR Part 29, which require compounding pharmacies to maintain sterile or non-sterile compounding accreditation, depending on the formulation type.

Methimazole oral capsules or suspensions are non-sterile preparations. A licensed 503A pharmacy in New York can legally prepare them when a prescriber determines that the commercially available tablet is not appropriate for a specific patient. Common clinical justifications include difficulty swallowing tablets (pediatric or elderly patients), allergy to tablet excipients, or the need for a non-standard dose not available commercially (for example, 2.5 mg for fine-titration in pediatric Graves disease).

Cost for compounded methimazole in New York varies. Some 503A pharmacies that work with telehealth platforms bill little or nothing out of pocket if the compounding fee is bundled into a membership or subscription model. Others charge $20, $60 per month depending on dose, base, and quantity. Compounded preparations are not interchangeable with FDA-approved branded or generic methimazole and are not covered by most commercial insurance plans; Medicaid does not cover compounded methimazole unless the FFS program issues a specific exception.

The FDA does not list methimazole on its Demonstrably Difficult to Compound (DDC) list or its 503B bulks list as of early 2025, so compounding remains permissible under current federal policy [9]. The New York State Board of Pharmacy can be contacted directly at (518) 474-3817 to verify a specific pharmacy's licensure status.

Methimazole for Hyperthyroidism: The Clinical Evidence Base

Methimazole's efficacy in Graves hyperthyroidism is supported by decades of controlled trial data. Cooper's landmark 2005 review in the New England Journal of Medicine described methimazole as producing euthyroidism in the majority of Graves patients within 6 to 12 weeks at standard doses of 10 to 40 mg/day, with remission rates of approximately 30 to 50% after 12 to 18 months of continuous therapy [10]. That paper remains one of the most-cited references in thyroid pharmacology.

A 2019 Cochrane systematic review of antithyroid drugs in Graves disease (11 RCTs, N=1,153) found that methimazole achieved significantly faster normalization of free T4 compared with propylthiouracil (PTU), with a mean difference of approximately 2 weeks in time to euthyroidism [11]. Methimazole's longer half-life (6 to 8 hours versus PTU's 1 to 2 hours) supports once-daily dosing in most patients, which improves adherence.

The ATA and the American Association of Clinical Endocrinology (AACE) jointly published management guidelines in 2016 recommending methimazole over PTU for nearly all adults with Graves disease except during the first trimester of pregnancy [4]. PTU is preferred in the first trimester because methimazole has been associated with a specific pattern of birth defects (aplasia cutis, choanal atresia, esophageal atresia) at a rate estimated at 2, 4 per 1,000 exposed pregnancies [12]. After the first trimester, guidelines recommend switching back to methimazole.

Agranulocytosis is the most serious adverse effect. The incidence is approximately 0.1 to 0.5% and occurs most often within the first 90 days of therapy [13]. The FDA prescribing information for methimazole instructs patients to report sore throat, fever, or mouth sores immediately, and prescribers should obtain a baseline complete blood count [1]. A white blood cell count below 1,000 cells/microliter (absolute neutrophil count <500) requires immediate drug discontinuation.

Liver toxicity is rare with methimazole (mild transaminase elevation in roughly 0.5% of patients) but more common with PTU, which carries an FDA black-box warning for severe hepatotoxicity [14]. This safety difference, combined with the dosing convenience, is why methimazole is the standard first-line choice.

Insurance Coverage for Methimazole in New York

Most commercial insurance plans sold in New York cover generic methimazole on Tier 1 or Tier 2 of their formularies, resulting in copays of $0, $15 per 30-day fill after deductible. Empire BlueCross BlueShield, United Healthcare Oxford, Aetna, and Cigna all include generic methimazole on their standard New York formularies. Brand Tapazole is typically placed on Tier 3 or higher, with copays of $40, $80 before step-therapy requirements are satisfied.

New York State requires insurers to cover FDA-approved prescription drugs for thyroid disorders when medically necessary, consistent with the state's essential health benefit (EHB) benchmark under the Affordable Care Act [15]. This means qualified health plans (QHPs) sold through NY State of Health cannot exclude methimazole from their formularies entirely, though they can place it on a non-preferred tier and require PA or step therapy.

For employees covered under self-insured ERISA plans, the state EHB mandate does not apply because ERISA preempts state insurance law. However, most large self-insured employers in New York (including those in finance, healthcare, and government) include methimazole on their drug benefits by default due to its low cost and high clinical necessity.

Medicare Part D covers methimazole. It appears on the formularies of all major Part D stand-alone prescription drug plans (PDPs) operating in New York, including AARP MedicareRx, SilverScript, and Humana Walmart Rx. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D beneficiaries (effective January 2025), methimazole costs are capped within that overall ceiling [16].

Telehealth Prescribing of Methimazole in New York

New York permits telehealth prescribing of methimazole for established diagnoses of hyperthyroidism. State law (New York Public Health Law Section 2999-cc) defines telehealth broadly and allows prescribing after a valid prescriber-patient relationship has been established through a synchronous audio-video encounter [17]. Methimazole is not a controlled substance, so the stricter DEA in-person requirements for Schedule II, V drugs do not apply.

A telehealth visit for methimazole typically requires the patient to have recent lab work: TSH, free T4, and in some cases free T3 and a thyroid-stimulating immunoglobulin (TSI) or thyrotropin receptor antibody (TRAb) level to confirm Graves disease. Most telehealth platforms instruct patients to obtain labs through Quest Diagnostics or LabCorp before the video visit. New York has over 240 Quest and LabCorp draw sites, including locations in all five boroughs, Nassau, Suffolk, and Westchester counties.

Telehealth endocrinology visits in New York typically cost $75, $200 per session without insurance. With insurance, the cost falls to the plan's specialist copay, usually $40, $75. Some direct primary care (DPC) practices in New York offer thyroid management, including methimazole prescribing, as part of a flat monthly membership fee of $75, $150.

The prescription itself is sent electronically to any New York licensed pharmacy. Patients may also use mail-order pharmacies licensed in New York to receive a 90-day supply, which further reduces per-day cost. A 90-day supply of generic methimazole 10 mg via mail order typically costs $25, $35, or roughly $8, $12 per month.

Savings Strategies: Getting the Lowest Price in New York

Several concrete strategies reduce methimazole out-of-pocket cost in New York.

GoodRx and competitor coupon apps. GoodRx, RxSaver, and Blink Health negotiate discounted prices at retail pharmacies. At Costco Pharmacy in New York, methimazole 10 mg (30 tablets) has been listed as low as $9 with a GoodRx coupon. These prices are accessible to any patient regardless of insurance status, though using a coupon means the fill does not count toward an insurance deductible [18].

Pfizer patient assistance. Pfizer offers the RxPathways program for brand Tapazole, providing free or reduced-cost medication to patients who meet income criteria (generally household income at or below 400% of the federal poverty level) and who lack adequate insurance. Applications are submitted through Pfizer's medical team or via the NeedyMeds database [19].

NeedyMeds and state pharmaceutical assistance. The NeedyMeds database (needymeds.org) lists patient assistance programs (PAPs) and disease-specific funds for thyroid conditions. New York does not operate a state-run pharmaceutical assistance program specifically for working-age adults with thyroid disease, but the Elderly Pharmaceutical Insurance Coverage (EPIC) program assists New York residents aged 65 and older by covering Medicare Part D cost-sharing [20].

90-day supplies. Requesting a 90-day supply instead of 30-day fills typically reduces per-unit cost. Most New York commercial plans allow 90-day fills at mail-order pharmacies at two times the 30-day copay, effectively providing one month free.

Switching to generic. If a prescriber wrote for brand Tapazole, asking the pharmacist to substitute FDA-approved generic methimazole (permissible unless the prescription bears "Dispense as Written") cuts cost from $80 to roughly $15 per month.

The HealthRX Methimazole Cost-Reduction Decision Framework for New York patients:

1. Confirm the prescription is written for generic methimazole (not brand Tapazole) and that "DAW" is not checked.
2. Run a GoodRx or RxSaver search for your specific ZIP code before leaving the prescriber's office.
3. If insured, check whether your plan's mail-order pharmacy offers a 90-day supply at a lower effective monthly rate.
4. If uninsured or underinsured, apply to NY State of Health for Medicaid or a subsidized QHP before paying cash price.
5. If you cannot swallow standard tablets or require a non-standard dose, ask your prescriber about a 503A compounding pharmacy referral.
6. If income qualifies, apply to Pfizer RxPathways for brand assistance or NeedyMeds for generic PAP referrals.

Monitoring Requirements That Affect Total Treatment Cost

Methimazole therapy requires laboratory monitoring that adds to total treatment cost beyond the drug itself. Standard monitoring per ATA 2016 guidelines includes TSH and free T4 every 4 to 6 weeks during the first 6 months, then every 3 to 6 months once stable [4]. A TSH lab draw at a New York clinical laboratory costs $30, $80 without insurance. With insurance, it typically applies toward the deductible or is covered at the preventive benefit rate for patients with established diagnoses.

Baseline liver function tests (LFTs) and a complete blood count (CBC) are recommended before starting methimazole. Follow-up CBC is obtained if a patient develops fever, sore throat, or signs of infection, given the agranulocytosis risk [1]. Thyroid ultrasound is occasionally ordered to assess gland size or nodule status; in New York, an outpatient thyroid ultrasound costs $200, $600 without insurance, though it is typically covered by commercial plans and Medicaid with appropriate diagnosis codes.

A 2021 study in Thyroid (N=854 Graves disease patients) found that the total annual direct medical cost of antithyroid drug therapy was $1,247 per patient, including medication, monitoring labs, and outpatient visits, compared with $3,892 for radioactive iodine therapy and $8,614 for thyroidectomy in the first year [21]. This cost advantage makes methimazole the most affordable first-line option for most New York patients, provided adherence is maintained and monitoring is not skipped.

Methimazole Dosing Reference for New York Prescribers

Standard initial dosing for Graves hyperthyroidism in adults is 10 to 40 mg per day, typically divided into two doses for doses above 20 mg/day, though once-daily dosing of 10 to 15 mg is effective for mild-to-moderate disease [4]. The FDA-approved prescribing information supports doses up to 60 mg/day for severe hyperthyroidism [1].

Pediatric dosing is weight-based: 0.4 mg/kg/day as the starting dose, divided into three doses, per the package insert. For a 30 kg child, that is approximately 12 mg/day divided as 4 mg three times daily [1]. Pediatric Graves disease accounts for roughly 10 to 15% of all Graves cases and is managed by pediatric endocrinologists at centers including NYU Langone, Columbia CUIMC, and NewYork-Presbyterian [22].

Maintenance doses are typically 5 to 15 mg/day once euthyroidism is achieved. Duration of therapy ranges from 12 to 18 months for a first course, after which drug is tapered and TSH is monitored for relapse. Approximately 50 to 60% of patients relapse within 12 months of stopping methimazole, particularly those with large goiters, high initial TRAb titers, or ongoing smoking [10].